drugset / Trial / NCT02022306

TD-6450 SAD and MAD in Healthy Subjects

NCT02022306

Phase 1 Completed 111 enrolled Theravance Biopharma
RandomizedParallel-groupTriple-blindTreatment

Summary

This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.

Timeline

Start
2014-02
Primary completion
2014-08
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator TD-6450 Unknown Oral